Contributors

Angela M. Acquaviva, Section on Growth and Development, Molecular, Cellular, and Nutritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Eli Y. Adashi, Department of Obstetrics and Gynecology, University of Maryland, Baltimore, Maryland 21201

Kerstin Albertsson-Wikland, Department of Physiology, University of Goteborg, S-400 33 Goteborg, Sweden

G. P. August, Department of Pediatrics, Children's Hospital, National Medical Center, Washington, D.C., 20010

Sameul D. Balk, Department of Pathology, New England Deaconess Hospital, Boston, Massachusetts 02116

D. R. Bangham, National Institute for Biological Standards and Control, London NW3 6RB, England

J. J. Bell, Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York 10032

CarolJ. Berry, Department of Medicine and Clinical Research Facility, Emory University School of Medicine, Atlanta, Georgia 30322

Thomas A. Bewley, Laboratory of Molecular Endocrinology, University of California, San Francisco, California 94143

Juergen R. Bierich, Department of Pediatrics, University of Tubingen, 74 Tubingen, Federal Republic of Germany

Louise Bilezikjian, The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037

S. L. Blethen, Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri 63110

Robert M. Blizzard, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

P. Bohlen, Neuroendocrinology Laboratories, Salk Institute, San Diego, California 92037 Johnny Brandt, KabiVitrum AB, Research and Development, Departments of Biochem­

istry and Analytical Chemistry, S-112 87 Stockholm, Sweden P. Brazeau, Laboratoire de neuroendocrinologie experimentale, H6pital Notre-Dame,

Montreal, Quebec, H21 4K8 Canada A. Briskin, Neuroendocrinology Laboratories, Salk Institute, San Diego, California 92037 D. R. Brown, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota

55455

643

644 Contributors

C. Bruno Bruni, Section on Growth and Development, Molecular, Cellular, and Nutritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Pierre Chatelain, INSERM U 34, Hopital Debrousse, 69005 Lyon, France Rajender K. Chawla, Department of Medicine and Clinical Research Facility, Emory

University School of Medicine, Atlanta, Georgia 30322 David R. Clemmons, Department of Pediatrics, University of North Carolina, School of

Medicine, Chapel Hill, North Carolina 27514 Vittorio Coiro, Department of Physiology, University of Massachusetts Medical School,

Worcester, Massachusetts 01605 The Committee on Growth Hormone Usage (S. L. Kaplan, G. P. August, S. A. Kaplan, M.

H. MacGillivray, W. V. Moore,j. S. Parks, A. F. Parlow, A. W. Root, T. P. Foley, A. E. Wilhelmi, and L. E. Underwood, A. j. johanson), The National Hormone andPitu­itary Program, University of Maryland School of Medicine,Baltimore,Maryland 2120 1

Michael P. Czech, Department of Biochemistry, University of Massachusetts Medical School, Worcester, Massachusetts 01605

William H. Daughaday, Metabolism Division, Washington University School of Medicine, St. Louis, Missouri 63110

Heather j. Dean, Departments of Physiology and Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada R3E OW3

A. joseph D'Ercole, Department of Pediatrics, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

David B. Donner, Memorial Sloan-Kettering Cancer Center and The Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Andrea Dorato, Memorial Sloan-Kettering Cancer Center and The Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Staffan Eden, Department of Physiology, University of Goteborg, S-400 33 Goteborg, Sweden

Catherine A. Egli, Department of Pediatrics, University of California-San Francisco, San Francisco, California 94143

F. Esch, Neuroendocrinology Laboratories, Salk Institute, San Diego, California 92037 Rina Eshet, Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical

Center, Petah Tikva 49 100, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

William S. Evans, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

Angel Ferrandez, Hospital Infantil, E-S0009, Zaragosa, Spain Timothy j. Fields, Department of Life Sciences, Indiana State University, Terre Haute,

Indiana 47809 T. P. Foley, Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania

15213 S. Douglas Frasier, Department of Pediatrics and Physiology/Biophysics, University of

Southern California School of Medicine and the Los Angeles County-University of Southern California Medical Center, Los Angeles, California 90033

Ulf Friberg, Department of Histology, Karolinska Institutet, S-l 040 1 Stockholm, Sweden Henry G. Friesen, Departments of Physiology and Pediatrics, University of Manitoba,

Winnipeg, Manitoba, Canada R3E OW3

Contributors 645

Luciano G. Frigeri, The Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037

Herwig Frisch, Department of Endocrinology, University-Kinderklinik Stien, A-1090 Wien IX-Vienna, Austria

Lawrence A. Frohman, Division of Endocrinology and Metabolism, Department of In­ternal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267

Lindo Fryklund, KabiVitrum AB, Research and Development, Departments of Biochem­istry and Analytical Chemistry, S-112 87 Stockholm, Sweden

Richard Furlanetto, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104

Lynne A. Gaynes, Endocrine Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205

Michael D. Geier, Genentech, Inc., South San Francisco, California 94080 Marie C. Gelato, Developmental Endocrinology Branch, National Institutes of Health,

Bethesda, Maryland 20205 G. Yancey Gillespie, Department of Surgery and Cancer Research Center, University of

North Carolina, School of Medicine, Chapel Hill, North Carolina 27514 James H. Goldman, Endocrine Division, Department of Medicine, Tufts University School

of Medicine, New England Medical Center, Inc., Boston, Massachusetts 02111 H. Maurice Goodman, Department of Physiology, University of Massachusetts Medical

School, Worcester, Massachusetts 01605 Genevieve Grichting, Department of Physiology, University of Massachusetts Medical

School, Worcester, Massachusetts 01605 Melvin M. Grumbach, Department of Pediatrics, University of California-San Francisco,

San Francisco, California 94143 R. Guillemin, Neuroendocrinology Laboratories, Salk Institute, San Diego, California

92037 Magnus Hagerman, KabiVitrum AB, Research and Development, Departments of Bio­

chemistry and Analytical Chemistry, S-112 87 Stockholm, Sweden David A. Harris, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 Berthold P. Hauffa, Departments of Pediatrics, University of California-San Francisco,

San Francisco, California 94143 William P. Heath, Department of Medicine and Clinical Research Facility, Emory Uni­

versity School of Medicine, Atlanta, Georgia 30322 Raymond L. Hintz, Department of Pediatrics, Stanford University, Stanford, California

94305 N.J. Hopwood, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan

48109 James P. Hughes, Department of Life Sciences, Indiana State University, Terre Haute,

Indiana 47809 J. Anthony Hulse, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 Rene E. Humbel, Biochemisches Institut, Universitat Zurich, Switzerland Chung Ho Hung, Section of Pediatric Endocrinology, Department of Pediatrics, University

of Kansas Medical Center; Kansas City, Kansas 66103 Ruth IUig, Universitatas Kinderklinik, CH-8032 Zurich, Switzerland

646 Contributors

oUe G. P. Isaksson, Department of Physiology, University of Goteborg, S-400 33 Goteborg, Sweden

H. Iwamoto, Department of Pediatrics, University of California-San Francisco, San Francisco, California 94143

John-Olov Jansson, Department of Physiology, University of Goteborg, S-400 33 Gote­borg, Sweden

Ann J. Johanson, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

Andrew J. S. Jones, Genentech, Inc., South San Francisco, California 94080 Susan Joyce, Department of Psychology, University of Virginia, Charlottesville, Virginia

22901 Donald L. Kaiser, Department of Pediatrics, University of Virginia School of Medicine,

Charlottesville, Virginia 22901 Selna L. Kaplan, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 Susan Kasper, Departments of Physiology and Pediatrics, University of Manitoba, Win­

nipeg, Manitoba, Canada R3E OW3 R. T. Kirkland, Department of Pediatrics, University of Texas, Houston, Texas 77030 J. Kitterman, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 Jack L. Kostyo, Department of Physiology, University of Michigan Medical School, Ann

Arbor, Michigan 48109 Karen Kover, Section of Pediatric Endocrinology, Department of Pediatrics, University

of Kansas Medical Center, Kansas City, Kansas 66103 A. Avinoam Kowarski, Department of Pediatrics, University of Maryland School of

Medicine, Baltimore, Maryland 21201 Michael H. Kutner, Department of Biometry and Clinical Research Facility, Emory

University School of Medicine, Atlanta, Georgia 30322 ZviLaron, Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical Center,

Petah Tikva 49 100, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Urban J. Lewis, The Whittier Institute for Diabetes and Endocrinology, La Jolla, California 92037

Choh Hao Li, Laboratory of Molecular Endocrinology, University of California, San Francisco, California 94143

Samuel Libber, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

N. Ling, Neuroendocrinology Laboratories, Salk Institute, San Diego, California 92037 Kenneth E. Lipson, Memorial Sloan-Kettering Cancer Center and The Sloan-Kettering

Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Robert H. Lustig, Department of Pediatrics, University of California-San Francisco, San Francisco, California 94143

Margaret H. MacGillivray, Department of Pediatrics, State University of New York at Buffalo School of Medicine and The Children's Hospital of Buffalo, Buffalo, New York 14222

Kjell Madsen, Department of Histology, Karolinska Institutet, S-10401 Stockholm, Sweden

Joseph B. Martin, Neuroendocrinology Laboratory, Department of Neurology, Massa­chusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

Contributors 647

Synthia H. Mellon, Metabolic Research Unit, Department of Medicine, University of California, San Francisco, California 94143

George R. Merriam, Developmental Endocrinology Branch, National Institutes of Health, Bethesda, Maryland 20205

Claude J. Migeon, Department of Pediatrics, Johns Hopkins University School of Med­icine, Baltimore, Maryland 21205

Tina Mitchell, Department of Psychology, University of Virginia, Charlottesville, Virginia 22901

Mark E. Molitch, Center for Endocrinology, Metabolism, and Nutrition and Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611

Wayne V. Moore, Section of Pediatric Endocrinology, Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas 66103

Cristina MoUola, Department of Biochemistry, University of Massachusetts Medical School, Worcester, Massachusetts 01605

S. Peter Nissley, Endocrine Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205

John V. O'Connor, Genentech, Inc., South San Francisco, California 94080 Yoshitomo Oka, Department of Biochemistry, University of Massachusetts Medical School,

Worcester, Massachusetts 01605 Kenneth C. Olson, Genentech, Inc., South San Francisco, California 94080 M. R. Pandian, Nichols Institute, San Juan Capistrano, California 92675 John S. Parks, Department of Pediatrics, Emory University School of Medicine, Atlanta,

Georgia 30322 Bohdan Pavlu, KabiVitrum AB, Research and Development, Departments of Biochem­

istry and Analytical Chemistry, S-112 87 Stockholm, Sweden Marilyn Perrin, The Clayton Foundation Laboratories for Peptide Biology, The Salk

Institute, La Jolla, California 92037 Athalia Pertzelan, Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical

Center, Petah Tikva 49 100, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

John A. Phillips III, Division of Genetics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

L. S. Phillips, Division of Endocrinology and Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30303

W. Jackson Pledger, Department of Pharmacology and Cancer Research Center, Uni­versity of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

Leslie P. Plotnick, Department of Pediatrics, Johns Hopkins University School of Med­icine, Baltimore, Maryland 21205

Michael A. Preece, Department of Growth and Development, Institute of Child Health, University of London, London WCIN lEH, England

Salvatore Raiti, The National Hormone and Pituitary Program, University of Maryland School of Medicine, Baltimore, Maryland 21201

Matthew M. Rechler, Section on Growth and Development, Molecular, Cellular, and Nutritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Seymour Reichlin, Endocrine Division, Department of Medicine, Tufts University School of Medicine, New England Medical Center, Inc., Boston, Massachusetts 02111

Jean Rivier, The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037

648 Contributors

Alan D. Rogol, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

Joyce A. Romanus, Section on Growth and Development, Molecular, Cellular, and Nu­tritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Diges­tive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Stephen M. Rosenthal, Department of Pediatrics, University of California-San Francisco, San Francisco, California 94143

Michael J. Ross, Genentech, Inc., South San Francisco, California 94080 DanielRudman, Department of Medicine and Clinical Research Facility, Emory University

School of Medicine, Atlanta, Georgia 30322 A. M. Rudolph, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 William E. Russell, Department of Pediatrics, University of North Carolina, School of

Medicine, Chapel Hill, North Carolina 27514 Libbie J. Russo, Section of Pediatric Endocrinology, Department of Pediatrics, University

of Kansas Medical Center, Kansas City, Kansas 66103 Genevieve Sassolas, Centre de Medecine Nucleaire, Hopital Neuro-Cardiologique, 69394

Lyon Cedex 3, France Paul SawchenkO, Developmental Neurobiology Laboratory, The Salk Institute, La Jolla,

California 92037 Jeanette M. Schepper, Department of Life Sciences, Indiana State University, Terre

Haute, Indiana 47809 Elizabeth A. Schriock, Department of Pediatrics, University of California-San Francisco,

San Francisco, California 94143 Hans Seifert, The Clayton Foundation Laboratories for Peptide Biology, The Salk

. Institute, La Jolla, California 92037 Morton B. Sigel, The Whittier Institute for Diabetes and Endocrinology, La Jolla,

California 92037 Aviva Silbergeld, Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical

Center, Petah Tikva 49 100, Israel, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Bo Skoog, KabiVitrum AB, Research and Development, Departments of Biochemistry and Analytical Chemistry, S-112 87 Stockholm, Sweden

Eric P. Smith, Department of Pediatrics, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

Joachim Spiess, The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, California 92037

D. M. Styne, Department of Pediatrics, University of California-Davis, Davis, California 95616

Marjorie E. Svoboda, Department of Pediatrics, University of North Carolina, School of Medicine, Chapel Hill, North Carolina 27514

Larry Swanson, Developmental Neurobiology Laboratory, The Salk Institute, La Jolla, California 92037

Marta Szabo, Division of Endocrinology and Metabolism, Michael Reese Hospital, Chicago, Illinois 60616

J. M. Tanner, Department of Growth and Development, Institute of Child Health, University of London, London WCIN lEH, England

Jeffrey E. Terrell, Section on Growth and Development, Molecular, Cellular, and Nutri­tional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Contributors 649

Jennifer L. Tlwminet, Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267

MichaelO. Thorner, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia 22901

Robert A. Tolman, Endocrinology Research Program, Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Gene F. Tutwiler, McNeil Pharmaceutical, Spring House, Pennsylvania 08540 Louis E. Underwood, Department of Pediatrics, University of North Carolina, School of

Medicine, Chapel Hill, North Carolina 27514 T. G. Unterman, Center for Endocrinology, Metabolism and Nutrition, Northwestern

University Medical School, Chicago, Illinois 60611 Wylie Vale, The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute,

La Jolla, California 92037 Mary Lee Vance, Department of Pediatrics, University of Virginia School of Medicine,

Charlottesville, Virginia 22901 Willard P. Vanderlaan, The Whittier Institute for Diabetes and Endocrinology, La Jolla,

California 92037 G. Van Vliet, Department of Pediatrics, University of California-San Francisco, San

Francisco, California 94143 Judson J. Van Wyk, Department of Pediatrics, University of North Carolina, School of

Medicine, Chapel Hill, North Carolina 27514 Joan Vaughan, The Clayton Foundation Laboratories for Peptide Biology, The Salk

Institute, La Jolla, California 92037 W. B. Wehrenberg, Neuroendocrinology Laboratories, Salk Institute, San Diego, Cali­

fornia 92037 Lisa L. Wheeler, Department of Life Sciences, Indiana State University, Terre Haute,

Indiana 47809 Robert M. White, Howard University Cancer Center, Departments of Oncology and

Medicine, Howard University School of Medicine, Washington, D.C. 20059 Harvey J. Whitfield, Section on Growth and Development, Molecular, Cellular, and

Nutritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Insitutes of Health, Bethesda, Maryland 20205

Anders Wichman, KabiVitrum AB, Research and Development, Departments of Bio­chemistry and Analytical Chemistry, S-112 87 Stockholm, Sweden

Kazuyo Yamada, Memorial Sloan-Kettering Cancer Center and The Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021

Yvonne W.-H. Yang, Section on Growth and Development, Molecular, Cellular, and Nutritional Endocrinology Branch, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20205

Kin-Tak Yu, Department of Biochemistry, University of Massachusetts Medical School, Worcester, Massachusetts 01605

Klaus Zuppinger, Inselspital, CH-30 1 0 Bern, Switzerland

Index

Acetylcholine GH release and, 418 hypothalamic somatostatin and, 415, 417,

418 somatostatin and, 316 TSH and, 418

Acidophil stem cell, 31 Acromegaly, 29

dopamine agonists in, 314 GH in, 36-40 GHRH and, 41 GRF-secreting pancreatic tumor in, 326 hpGRF-40 in, 365-366 hyperprolactinemia in, 30, 381 somatomedin C in, 615 TRH in, 310

ACTH,3 Actinomycin D, glucose oxidation and, 506,

507 Adenoma

GRF and, 349 mammosomatotroph cell, 31

Adenylate cyclase GH and, 475

activity of, 496 hypophysectomy and, 493, 494, 495

Adipocytes, GH and, 499-512 Adipose tissue, 499

response to GH, exercise and, 503 Adrenal adenoma, GRF and, 349 Affinity chromatography

in analysis of SM binding protein, 557 in isolation of GH receptor, 455, 456, 458-

459 Alkaline phosphatase, hGH and, 271 Allergic diathesis, 273 Amino acid

analysis, in purification of SMC, 523 GH secretion and, 317 ,(-aminobutyric and, 317

Amino acid (cont.) GH release and, 418 GH secretion and, 317 somatostatin release and, 414, 416, 418 TSH and, 418

Amniotic fluid, SM binding proteins in, 556, 557

Androgens, somatomedin C and, 613 Androgen-stimulating hormone, 4 Anorexia nervosa, GH hypersecretion and, 43,

44 Antidiuretic hormone, deficiency, 68 Anti-E. coli assay, in preparation of met-hGH,

251-254,261,263 Anxiety, GH hypersecretion and, 43 Aortic stenosis, in LTD, 165 Apomorphine

for GH testing, 317 hGH stimulation by, 315

Arginine, in diagnostic test for GH deficiency, 54

Autoimmune diseases, from denatured hormones, 236

Beckwith-Wiedemann syndrome, somatomedins and, 631

Birth trauma, GH deficiency, 59 Blood sugar, hpGRF-40 and, 363 Blood urea nitrogen, hGH and, 271 Bombesin,4

GH and, 311, 312 GH release of, 418 hypothalamic somatostatin and, 416, 418 TSH and, 418

Bone growth, see also Cartilage growth longitudinal

hGH and, 564-566 measurement of, 565 prolactin and, 565

Brain, somatostatin receptors in, 420

651

652

Brain stem, somatostatin, 407 Bromocriptine

in GH testing, 376 hGH stimulation by, 315

Calcitonin, as tumor marker, 375 Calcium

GH release and, 334 hGH binding and ions of, 482, 484 release of, 414 somatostatin and, 420

Calcium-regulating factor, 4 Cancer, GH levels and, 41 Carcinoid tumor, GRF-secreting, 348, 349 Carcinoma, GRF immunoreactivity, 354 Cartilage growth, see also Bone growth

GH and, 563-573 Cataract, in LTD, 165 Catecholamines

GH and, 500 hGRF 1-44-NH2 and, 394

Cerebral cortex, somatostatin in, 407 Children, prepubertal, GRF in, 382 Cholecystokinin,

GH release and, 418 hypothalamic somatostatin and, 416 TSH and, 418

Cholera toxin, somatomedin C and, 597 Chondrocytes

GH binding sites, 566 thymidine incorporation, 568-570

Chorionic gonadotropin, see Human chorionic gonadotropin

Chorionic somatomammotropin, see Human chorionic somatomammotropin

Chromatography affinity, 455, 456, 458-459, 557 high-performance liquid, 523, 525 ion exchange, 450, 455

Cirrhosis, GH hypersecretion and, 43, 44 Clonidine

in diagnostic test for GH deficiency, 54 for GH testing, 317

Corticotropin hyGRF-40 and, 362-363 purification, 21

Corticotropin-releasing factor, 4 Cortisol, hGRF 1-44-NH2 and, 394 Craniopharyngioma, GH deficiency and, 59,

137, 383, 389 Crescormon, 257; see also Human growth

hormone radio labeled, preparation of, 259 versus Somatonorm, 258, 287-300 versus Somatonorm I, 290

Cyclic AMP GH and, 500

Index

hpGRF and production of, 334 hypothalamic somatostatin and, 416, 417 rhGRF and production of, 334

Cycloheximide, glucose oxidation and, 506, 507

Cyproheptadine, hGH release and, 316

De Morsier's syndrome, GH deficiency in, 57 Depression, GH hypersecretion and, 43 Dexamethasone, effect on GH mRNA, 182 Diabetes mellitus

GH hypersecretion and, 43, 44 hpGRF and, 370 IGF-I and, 631 IGF-II and, 631

Dibuteryl AMP, somatomedin C and, 597 Diencephalic syndrome

GH hypersecretion in, 43 somatomedin and, 43

DNA synthesis IGF-II receptor and, 547 insulin receptor and, 543 somatostatin C and, 525 somatostatin, 525, 587, 588

Dopamine agonists, in acromegaly, 314 GH release and, 418 GH stimulation by, 314-315 hypothalamic somatostatin and, 415, 417,

418 somatostatin and, 316 TSH secretion and, 418

Dwarfism Laron-type, 42-43, 58, 163-176; see also

Laron-type dwarfism

Ectopic GRF syndrome, 347-360 Electroimmunoassay, 258, 261 Electron microscopy, 29 Electrophoresis

paper, 523, 524 polyacrylamide gel, 235

Empty sella syndrome distinguished from pituitary tumor, 58 GH deficiency in, 57-58

Endorphins GH release and, 418 hypothalamic somatostatin and, 416, 417,

418 TSH and, 418

Enkephalins, GH and, 311, 312 Ependymoma, GH deficiency and, 59

Index

Epidermal growth factor, somatomedins and, 588, 589

Escherichia coli polypeptide, in biosynthesis of somatonorm, 288

Estrogen, somatomedin C and, 613 Exercise, response to GH and, 503

Facial flushing, associated with GRF, 398 Fetal growth, insulinlike growth factor and,

621 Fibroblast

growth factors and, 570-571 somatomedin C production in, 490

Fluorography, 532 Follicle-stimulating hormone (FSH), 3

hGRF 1-44-NH2 and, 394 Forskolin, somatomedin C and, 597 FSH, see Follicle stimulating hormone

Ganglioneuroblastoma, GRF and, 352 Gas chromatography, 235 Gastrin

hpGRF-40 and, 363 as tumor marker, 375

Gel electrophoresis, in analysis of MSA, 529 Gel filtration, 450 Germinoma, GH deficiency and, 59, 383 GH, see Growth Hormone GHRH, see Growth hormone-releasing factor Giant cell granuloma, hypopituitarism

associated with, 60 Glioblastoma, GRF and, 349 Glucagon

in diagnostic test for GH deficiency, 54 GH and, 311, 312

release of, 418 hpGRF-40 and, 363 hypothalamic somatostatin and, 415, 416,

418 TSH and, 418 as tumor marker, 375

Glucocorticoids, GRF receptors and, 334 Glucose

hypothalamic somatostatin and, 416 oxidation

actinomycin D and, 506, 507 cycloheximide and, 506, 507 GH and, 501, 502, 505

Glucose tolerance test, met-hGH and, 271 Glycoprotein hormones, 6-7 Golgi apparatus, 485 Gonadoptropin, chorionic, see Human

chorionic gonadotropin (HCG) Growth hormone

acetylcholine and release of, 418

Growth hormone (cont.) in acromegaly, 36-40, 41 adenylate cyclase and, 475, 496 adipocytes and, 499-512 amino acids and secretion of, 317 -y-aminobutyric acid and, 317, 418 apomorphine in tests for, 317 binding in chondrocytes, 566 binding, liver receptors, 475-498 bioinactive, 58, 127-134 bombesin and, 311, 312,418 calcium and, 334 cancer and levels of, 41 cartilage growth and, 563-573 catecholamines and, 500 cholecystokinin and, 418 c10nidine in tests for, 317 cyclic AMP and, 500

653

deficiency, 51-65; see also Hypopituitarism, 56,59-62

acquired, 56, 59-62 in adults, 383 birth trauma and, 59 causes of, 55-62 in children, 384 clinical features, 52-53 congenital, 56, 57-59 craniopharyngioma and, 59, 137,383,389 in De Morsier's syndrome, 57 diagnostic tests for, 53-55 ependymoma and, 59 familial, 213, 389 gene disorders associated with, 211 germinoma and, 59, 383 gonadotropin deficiency in, 53 GRF in, 383-384 hGRF 1-44-NH2 in, 388-399 hpGRF-40 in, 366-369 in hyposomatomedinemia, 148 hypothalamic somatostatin and, 415 in hypothyroidism, 61 idiopathic, 213-224, 383, 389 inherited, 57 irradiation and, 60, 389 meningioma and, 59 met-hGH in, 268-277, 279-286, 287-300 molecular basis of, 212 optic gliomas and, 59 organic, 389 prenatal,214 radiation therapy and, 389 radioimmunoassay for determinating, 53 radioreceptor assay for detecting, 53 responses to hGH in, 150 secondary to bioinactive, 127-134

654

Growth hormone (cont.) deficiency (cont.)

sex variations in, 57 somatomedin C in, 614 subtle forms, 51 therapy for, 53, 67-75 tuberculous meningitis and, 389

depletion by overstimulation of GRF, 342 diabetogenic activity, 449 dopamine and, 314-315, 418 endorphins and, 311, 312, 418 feedback regulations of, 317-318 gene

delections, 216, 218 glucocorticoid regulations of, 180

gene cluster, 199-209,212 gene expression, 179-198

RNA polymerase 11 and, 189 glucagon and, 311, 312, 418 glucose oxidation and, 501, 502, 505 glycosylated, 443 GRF and, 334 harmonic secretion, 340 in histiocytosis, 61 human, see Human growth hormone (hGH) 5-hydroxytryptophan and secretion of, 316 hyperglycemia and secretion of, 36 hypersecretion, 29-50

anorexia nervosa and, 43, 44 anxiety and, 43 cancer and, 41 chronic renal failure and, 43, 44 cirrhosis and, 43, 44 depression and, 43, 44 diabetes mellitus and, 43, 44 in diencephalic syndrome, 43 in Laron-type dwarfism, 42-43 in McCune-Albright syndrome, 42 physical stress and, 43 protein-calorie malnutrition and, 43, 44 schizophrenia and, 43, 44 syndromes of, 30 systems diseases associated with, 43-45

hypoglycemia and, secretion of, 36, 37 hyposecretion, see Growth hormone,

deficiency hypothalamic regulation of, 304-307 identification, 234-235 insulin in tests for, 317 versus insulin, 505 insulinlike effect, 504-511

refractoriness associated with, 500, 501, 504, 508, 509, 510

international reference preparation (lRP), 230

Index

Growth hormone (cont.) intravenous pulse administration of, 388 Kupffer cell response to, 490 lactogenic property, 449 levodopa and release of, 313 levodopa in tests for, 317 localization in Golgi area, 485 in lung cancer, 41 malnutrition and levels of, 61 melatonin and, 418 metergoline and, 316 mRNA, effect of dexamethasone on, 182 MSG and, 310-311 multivalent nature of, 451 mutations of gene for, 130 naloxone and, 503, 504 neurotensin and, 311, 312, 418 nicotinic cholinergic agents and, 317 norepinephrine and, 313-314, 418 onset of action, 564 postoperative secretion, acromegalic patients,

40-41 prolactin receptors and, 480 propranolol and, 313 rate of secretion, 303 receptor

adsorption to organomercurial agarose, 457-458

affinity labeling, 463-473 aggregate structure, 471 fractionation, 457 immunoprecipitation, 459-460 isolation of, 455-461 molecular weights, 471 monoclonal antibody specific for, 458 role of disulfide bonds in stabilizing, 471 subunit, 471

reserves, assessing, 398 resistance to, see Growth hormone-resistant

syndromes RNA synthesis and, 507 secretin and, 418 serotonin and, 316, 418 sex steroids and, 604 somatomedins and, 303 somatostatin and, 413 substance P and, 311, 312, 418 in thalassemia major, 60 thyroid hormone and, 179, 181 TRH and, 310, 312, 418

in acromegaly, 37, 38 vasopressin and, 310, 312 verapamil and, 334 VIP and, 311, 312, 418

Index

Growth hormone-releasing factor, 55, 304, 307-309,318; see also Human hypothalamic growth-releasing factor; Human pancreatic growth-releasing factor

bovine, 338 facial flushing and, 398 in GH deficiency, 383-384 GH hypersecretion and, 29, 32-34 GH synthesis and, 334 human, see Human hypothalamic-growth

releasing factor; Human pancreatic growth-releasing factor

hGH and, 383 hyperproduction somatotroph hyperplasia

from, 381 mechanism of action, 309 menstrual cycle and GH responses to, 397 in normal prepubertal children, 382 versus other peptides, 308 overstimulation by, 342 pancreatic tumor secreting, 326, see also

Human pancreatic growth-releasing factor

pharmacokinetics, 370 porcine, 338 production of, 212 purification, 325 radioimmunoassay, 375 rat, 338

versus human, 338 receptor binding, 309 receptors, glucocorticoids and, 334 secretion, pancreatic tumor, 373 structure, 307 synthetic, 309 tumors secreting, 348-354

Growth hormone-resistant syndromes, 163-178

Hamartoma, hypopituitary, 357 Hand-Schuller-Christian disease, hpGRF-40 in,

366 Harelip, in LTD, 165 Hepatitis B antigen, 237 hhGRF, see Human hypothalamic growth­

releasing factor High-performance liquid chromatography, 234

in purification of met-hGH, 251 in somatome din C purification, 523, 525

Hip joint dislocation, in LTD, 165 Hippocampus, somatostatin in, 407 Histiocytosis, GH responses in, 61 Hormones, contaminants in, 234, 236

hpGRF, see Human pancreatic growth­releasing factor (hpGRF)

hpGRF-37 (OH), 337 hpGRF-40, 361-371

in acromegaly, 365-366 blood sugar and, 363 cholecystokinin and, 363 corticotropin and, 362-363 gastrin and, 363 in GH deficiency, 366-369 glucagon and, 363 in Hand-Schuller-Christian disease, 366 insulin and, 363 intranasal, 364 luteinizing hormone and, 362 metabolic clearance rate, 365 motilin and, 363 plasma lipids, 368 prolactin and, 362 purification, 326 somatomedin C and, 363 somatostatin and, 363 subcutaneous, 364-365 thyrotropin and, 362

hpGRF(40)-OH, 337 potency, 326 physiological effects, 363

hpGRF 1-37,373,387 hpGRF 1-40,373,381 hpGRF 1-40-0H, in GH deficiency, 388 hpGRF 44-NH2, 337, 373, 381

age and response to, 391, 393, 394, 397 for assessing releasable GH reserve, 398 catecholamine and, 394 continuous infusion, 395-396 cortisol and, 394 efficacy of, 398 FSH and, 394 in GH deficiency, 388 insulin and, 394 LH and, 394 in normal adult men, 382 potency, 326 prolactin and, 394 single pulse administration, 390-395 somatostatin and, 394 therapy, in GH deficiency, 388-399 TSH and, 394

Human chorionic gonadotropin (HCG), 4 distribution, 7-9 as tumor marker, 375

655

Human chorionic somatomammotropin (HCS), 199

absorption spectroscopy, 429-437 A gene, 205

656

HCS (cont.) B gene, 205 gene

DNase I sensitivity of, 206 localization of, 200 methylation of, 205 organization of, 20 I primary sequences of, 205

gene deletions, 206 gene variants, 200 versus hGH, 429-437 Lgene, 200, 203, 205 mRNA coding sequences, 212 primary sequence homology with hGH, 478 production of, 205

Human growth hormone (hGH) absorption spectroscopy, 429-437 acetylation of NH2 terminus of, 443 alkaline forms, 444 alkaline phosphatase and, 271 amino acid substitutions in, 441 antibodies to, 270, 272, 284 antigenic proteins in, 235 apomorphine and stimulation of, 315 binding to adipocytes, rate of, 509 binding to chondrocytes, 567 binding to liver membrane, 475-498, see also

Growth hormone, binding, liver receptors

versus bGH binding, 486 calcium ions and, 482, 484 cations and, 482, 484, 489 disulfide reduction and, 485, 486 electrolytes and, 482, 484, 489 irreversibility of, 483, 485 Kupffer cell, 490 macrophages, 491, 492 magnesium ions and, 482 pH and, 476, 482, 483, 489 potassium ions and, 484 sodium ions and, 484 temperature and, 485 time course, 486 in viro versus in vitro, 495

binding to prolactin receptors, 468 bioassay, 236-237 biological activities, 442 blood urea nitrogen and, 271 bromocriptine and stimulation of, 315 cloning of message of, 242 contamination of extracted, 234 crosslinking to hepatocytes, 466, 467, 468 cross-reactivity with prolactin, 478 cyproheptadine and release of, 316 deamidation, 441

Human growth hormone (cont.) deficiency, diagnosis of, 26 desamido forms, 443 diabetogenic activity, subtilisin and, 445 discovery, I disulfide dimer, 442 efficacy, 22 gene

DNase I sensitivity of, 206 DNA sequence of, 439 localization of, 200 methylation of, 205 organization of, 20 I primary sequence of, 205

gene responsible for encoding, 202 in GH deficiency, dose-response

relationships, 67-75 GRF and, 383 versus hCS, 429-439, 478 insulin and, 443

Index

insulin-potentiating properties, 443, 444-445 internalization to Golgi area, 496 international standard, 229-230 lactogenic activity, 468 longitudinal bone growth and, 564-566 lymphocyte binding, 495 melatonin and, 317 methionyl, 242, 243 methysergide and release of, 316 molecular structure, 303 molecule, flexibility in solution, 483 monocyte binding, 495 mRNA coding sequence multiple forms, 439-453 N gene, 202 phosphorus and, 271 phosphorylation, 445 piribedil and stimulation of, 315 pituitary, versus met-hGH, 247, 267-268,

270 preparation

contaminants, 236 purification, 236

produced by recombinant DNA, 237-239 production of, 205

release and, 211 prohormone hypothesis for, 440 prostaglandin E2 and, 317 radioimmunoassay, 2 receptors, see also Growth hormone, receptor

lactogenic nature, 476 on macrophages, 491 molecular weight, 496

somatedin C and, 271, 597, 640 spontaneous fluctuations in, 304

lruks

Human growth hormone (cont.) therapy, 67-75

long-term, 93-106 psychosocial evaluation of patients in, 93-

106 response to, 69-71 schedule of administration, 71-73 in short normal children, 123-126 subcutaneous versus intramuscular, 85-91 thyroid function in,. 119 in Turner's syndrome, 109-113, 115-121

thymidine incorporation and, 568, 569, 570 trytophan and, levels of, 316 tyrosine kinase phosphorylation of, 445 V gene, 203, 207

Human hypothalamic growth releasing factor, 337

hpGRF and, 326 Human pancreatic growth releasing factor

(hpGRF), 337 analogues, 331, 332 cyclic AMP production and, 334 in diabetes mellitus and, 370 hhGRF and, 326 high-affinity binding sites for, 334 nitrogen balance and, 370 precursors, 326 radioimmunoassay, 327, 328 versus rhGRF, 330 in wound healing, 370

Human placental lactogen, see Human chorionic somatomammotropin HCS)

Hybritech assay, 14, 151-152 Hydatidiform moles, 205 5-hydroxytryptophan, GH secretion and, 316 Hyperglycemia, GH secretion and, 36 Hyperprolactinemia, in acromegaly, 30, 381 Hypersomatotropism, secondary, 395 Hypoglycemia, GH secretion and, 36 Hypophysectomy, adenylate cyclase and, 493,

494 Hypopituitarism

diagnosis, 2 idiopathic, 96

hGH in, 79-80, 82 organic,96

hGH in, 80-81, 82 psychosocial stress and, 61 vascular lesions in etiology of, 60

Hyposomatomedinemia, 135-162 Hypothalamus

arcuate nucleus, 305 GH regulation and, 304-307 hamartoma, 357 median eminence, 306

Hypothalamus (cont.) periventricular nucleus, 305 preoptic region, 305 somatostatin in the, 407, 409, 415-416 suprachiasmatic nucleus, 305 ventromedial nucleus, 305

657

Hypothalamic germinoma, GH deficiency and, 383

Hypothyroidism, GH deficiency in, 61

Idiopathic growth hormone deficiency, see IGHD-IA, IGHD-IB, IGHD-II, IGF, see Insulinlike growth factor; Somatomedins

IGHD-IA,213-219 IGHD-IB,219-222 IGHD-II, 222-224 Immunoblotting assay, 249, 258, 261 Immunohistochemistry, 29 Immimoprecipitation, 532 Insulin

in diagnostic test for GH deficiency, 54 versus GH, 505 for GH testing, 317 hGH and, 443 hGRF 1-44-NH2 and, 394 hpGRF-40 and, 363 IGF-II receptor and, 546-548 receptor

DNA synthesis and, 543 versus IGF-I receptor, 541, 543 subunit, 471

Insulinlike growth factor birth weight and levels of, 629 fibroblast production of, 624

Insulinlike growth factor I, see also Somatomedin C

amino acid sequences, 516 binding to fetal membranes, 622-623 in cord serum, 603, 604 cross-reactivity, 518 diabetes mellitus and, 631 in dialysis patients, 606 in the elderly, 604 in hypopituitary children, 605 leprechaunism and, 631 protein intake and, 605 during puberty, 604 purification, 523, 524 radioimmunoassay, 576, 601, 602, 605 radio receptor assay, 576, 626 receptor, 539

antiserum, 545 disulfide linkage, 540 human placental, 541

658

Insulinlike growth factor I (cont.) receptor (cont.)

versus insulin receptor, 541, 543 structure of, 540-542

in uremia, 606 Insulinlike growth factor II, 303

amino acid sequences, 516-518 binding to fetal membranes, 622-623 in cord serum, 603, 604 cross-reactivity, 518 diabetes mellitus and, 631 in hypopituitary children, 605 protein intake and, 605 radioimmunoassay, 576, 627, 628, 629 radio receptor assay, 576, 601, 602, 605,

626-627 receptor, 539

antiserum, 539 cell growth and, 544 disulfide-linkage, 540 DNA synthesis and, 547 insulin and, 546-548 role of, 543-544 structure of, 540-542

Ion chromatography, 450 Ion exchange chromatography

in isolation of GH receptor, 455 in purification of met-hGH, 250

Irradiation, pituitary function and, 60 Isobutyl methylxanthine, somatomedin C and,

597 Isoelectric focusing, in somatomedin C

purification, 523

Jakob-Creutzfeldt syndrome, virus associated with, 234

Joyce measure, 94-95

Kallestad assay, 140-141, 151 Kupffer cell

as GH-responsive cell, 490 hGH-binding to, 490

Lambda bacteriophage, 201 Laron-type dwarfism, 42-43, 58, 163-176

birth weight of children with, 165 blood chemistry in, 169 congenital malformations in, 165 dentition in, 168 diurnal variation of hGH in, 172 as an example of resistance to GH, 171 facial appearance in, 167 genetic aspects, 164-165 hair growth in, 168 maximum height, 170 motor development in, 166

Laron-type dwarfism (cant.) sexual maturation in, 169

Index

similarity to idiopathic GH deficiency, 166 skeleton development in, 169 subcutaneous fat tissue, 168

"Lazy pituitary syndrome," 61 Leprechaunism, IGF-I and, 631 Levodopa

in diagnostic test for GH deficiency, 54 GH release stimulated by, 131 for GH testing, 317

LH, see Luteinizing hormone Lineweaver-Burk analysis, 581 Lipids, hpGRF-40 and, 368 Liver

receptors, GH binding to, 475-498 somatomedin C production and, 475 steroid metabolism in, hormonal control of,

480 Lung cancer, GH secretion in, 41 Luteinizing hormone (LH), 3, 236

hpGRF-40 and, 362 hGRF 1-44-NH2 and, 394

LTD, see Laron-type dwarfism Lymphocytes, hGH binding to, 495 Lymphocytic hypophysitis, 60

Macrophage hGH binding to, 491, 492 hGH receptors, 491

Magnesium, hGH binding and ions of, 482, 484

Malnutrition, GH levels in, 61 McCune-Albright syndrome, 42 Melanocyte stimulating hormone (MSH), GH

and, 310-311 Melatonin

GH release and, 418 hGH and, 317 hypothalamic somatostatin and, 416 TSH and, 418

Meningioma, GH deficiency and, 59 Meningitis, GH deficiency and, 389 Menstrual cycle, GH responses to GRF and,

397 Metergoline, GH release and, 316 met-hGH, see Methionyl human growth

hormone Methionyl human growth hormone (met-

hGH), 297; see also Somatonorm amino acid analysis, 267 antibodies to, 272 biological activity, 267 chromatographic pattern, 267

lruln

Met-hGH (cont.) in GH deficiency, 268-277, 279,--286, 287-

300 glucose tolerance test and, 271 versus pituitary hGH, 247, 267-268, 270 preparation of, 245-255

anti-E. coli assay in, 251-254 high pressure liquid chromatography in,

251 radioactive spike process validation in, 250

primary structure, 267 thyroxine and, 271

Methysergide, hGH release and, 316 Microcoulombetry, 235 Monoclonal antibody, for GH receptor, 458 Monocyte, hGH binding to, 495 Motilin, hpGRF-40 and, 363 MSA, see Multiplication-stimulating activity MSH, see Melanocyte stimulating hormone Multiplication-stimulating activity (MSA), 515,

529 fibroblast response, 624 precursor forms, 539-536 purification, 529, 557 thymidine incorporation and, 624

Naloxone, GH-responsiveness and, 503, 504 National Hormone and Pituitary Program

(NHPP),51 goal, I

National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, 13-18

National Pituitary Agency, 1 Neuroblastoma, GRF and, 349, 352 Neurofibroma, GRF and, 349 Neurohypophysis, somatostatin in, 407 Neurophysins, 4 Neurotensin

GH and, 311, 312,418 hypothalamic somatostatin and, 416, 417,

418 TSH and, 418

Nicotinic cholinergic agents, GH release and, 317

Nitrogen balance, hpGRF and, 370 Nonsuppressible insulinlike activity (NSILA),

515, 553 in vivo evidence of, 558

Norepinephrine GH and, 313-314, 418 hypothalamic somatostatin and, 415, 417,

418 somatostatin and, 316 TSH and, 418

659

NSILA, see Nonsuppressible insulinlike activity Nystagmus, in LTD, 165

Optic gliomas, GH deficiency and, 59 Oxandrolone, 51 Oxytocin, somatostatin and, 407

PAGE, see Polyacrylamide gel electrophoresis-sodium dodecyl sulfate

PAGE-SDS, see SDS-PAGE Pancreatic polypeptide, as tumor marker, 375 Pancreatic tumor

GRF-secreting, 326, 373 histopathological examination, 375, 377,

380-391 somatostatinlike substance from, 381

Paper electrophoresis, in somatomedin C purification, 523, 524

PDGF, see Platelet-derived growth factor Perthes' disease, in LTD, 165 Pheochromocytoma, GRF and, 349, 352 Phosphorus, hGH and, 271 Physical stress, GH hypersecretion and, 43 Piribedil, hGH stimulation by, 315 Pituitary gland

amount of hGH produced by, 440 diabetogenicity activity, 445 hormones from the, 5-6 somatostatin receptors in, 420 tumor, 29-36

Placental lactogen, see Human chorionic somatomammotropin (HCS)

Platelet-derived growth factor (PDGF) somatomedin C and, 597 somatomedins and, 588

Polyacrylamide gel electrophoresis-sodium dodecyl sulfate, see SDS-PAGE

Polyostotic fibrous dysplasia, 42 Potassium, hGH binding and ions of, 484 Prehormone, 201, 242 Preprosomatostatin, structure of, 410 Progesterone

radioimmunoassay, 586, 587 somatomedin C and, 586

Prohormone, somatostatin as, 413 Prohormone hypothesis, for hGH, 440 Prolactin, 3, 236

competition for hGH cross-linking, 469, 471 cross-reactivity with hGH, 478, 481 glycosylated, 443 hpGRF-40 and, 362 hGRF 1-44-NH2 and, 394 longitudinal bone growth and, 565 receptors

GH and, 480

660

Prolactin (cont.) receptors (cont.)

hGH binding to, 468 induction of, 479-480

thymidine incorporation and, 568-570 from tumors, 29

Propranolol in diagnostic test for GH deficiency, 54 GH release and, 313

Prostaglandin E2, hGH and, 317 Prostaglandins, hypothalamic somatostatin and,

416 Protein intake

IGH-I and, 605 IGF-II and, 605

Protein synthesis, steps in, 181 Protein-calorie malnutrition, GH

hypersecretion and, 43, 44 Proteins, tests for, 235 Protropin, see Human growth hormone (hGH)

Radiation therapy, GH deficiency and, 389 Radioimmunoassay, 9-10, 53

in analysis of somatomedin C, 525 biclonal, 141, 151-152 GRF,375 human growth hormone, 2 IGF-I, 576, 601, 602, 605 IGF-II, 576, 627, 628, 629 monoclonal, 141-142, 152 polycolonal, 140-141, 151 progesterone, 586, 587 somatomedin C, 610, 611

Radioreceptor assay, 53, 243 in analysis of somatomedin C, 525 IGF-I, 576, 626 IGF-II, 576, 601, 602, 605, 626-627 somatomedins, 575

Rat hypothalamic growth releasing factor (rhGRF)

analogues, 331 antibodies, 332 cyclic AMP production and, 334 versus hpGRF, 330 potency, 330 purification, 330

Receptor modulation assay, 243 Recombinant DNA technology, 244, 257

in production of hGH, 237-239 Renal failure, see also Uremia

chronic, GH hypersecretion and, 43, 44 rhGRF, see Rat hypothalamic growth releasing

factor RNA synthesis, GH and, 507

Index

Sarcoma, GRF and, 349 Schizophrenia, GH hypersecretion and, 43, 44 SDS-PAGE

detecting proteins on, 248 in isolation of GH receptor, 457 in purification of hGH, 246-248 silver gels, monitoring, 248, 261

Secretin GH secretion and, 418 hypothalamic somatostatin and, 416, 418 TSH and, 418

Septooptic dysplasia, 57 Serotonin

GH and, 316, 418 hypothalamic somatostatin and, 415, 418 TSH release and, 418

Sex steroids, GH and, 604; see also specific compounds

Sleep test, in hyposomatomedinemic children, 152, 154

SMC, see Somatomedin C Sodium, hGH binding and ions of, 484 Sodium dodecyl sulfate-polyacrylamide gel

electrophoresis, see SDS-PAGE Somatocrinin, see Growth hormone releasing

factor Somatomedin A, 515 Somatomedin B, 515 Somatomedin C

in acromegaly, 615 amino acid sequence, 518 androgens and, 613 binding to mononuclear cells from cord

blood,623 cell growth and, 525 in children, 609 cholera toxin and, 597 deficiency, in children, 135-162 in diagnostic test for GH deficiency, 54 dibuteryl AMP and, 597 DNA synthesis and, 525 in early childhood, 611 epidermal growth factor and, 588, 589 estrogen and, 613 fetal, 635-642 fibroblast production of, 490 forskolin and, 597 GH deficiency and, 614 hGH and, 271, 597, 640 hpGRF-40 and, 364 in hypopituitary children, 610 hypothalamic somatostatin and, 415, 418 isobutyl methylxanthine and, 597 liver and production of, 475 monoclonal antibodies to, 590-597

Index

Somatomedin C (cont.) natural versus synthesis, 2525, 526 nutritional status and, 615-616 PDGF and, 597 progesterone and, 586 during puberty, 611 purification, 523, 525 radioimmunoassay, 115, 116, 135, 525, 610-

611 radioreceptor assay, 525 in short children, 135-162 somatostatin release and, 317 structure, 521 synthesis, 521-522 synthetic versus natural, 525, 526 tissues responsive to, 588 TSH and, 418

Somatomedins Beckwith-Wiedemann syndrome and, 631 binding proteins, 544-559

affinity chromatographic analysis of, 557 in amniotic fluid, 556, 557 characterization of, 556-558 complex forms, 559 measurement of, 555-556 molecular weight, 557 purification, 557 role of, 558 subunits, 557

cell growth and, 585-597 defined,515 diencephalic syndrome and, 43 discovery, 516 DNA synthesis and, 587, 588 inhibitors

molecular weight, 579, 580 in serum, 581 in urine, 581

plasma, 553-554 platelet-derived factor and, 588 purification, 554 radioreceptor assay, 575 role in mediation of GH, 303 in uremia, 578

Somatonorm, see also Methionyl human growth hormone (met-hGH)

adsorbents for, 259 antibodies against, 293-297 antigenicity, 215, 260-264 contaminants, 261 versus Crescormon, 258, 287-300 E. coli polypeptide in biosynthesis, 288 radiolabeled, preparation of, 259

Somatonorm I, 279-286 allergic skin reactions from, 294

Somatonorm I (cant.) chronic treatment, 298 versus Crescormon, 290

Somatonorm II, 289 Somatostatin, 309, 310, 405-415; see also

Preprosomatostatin, structure of acetylcholine and, 316

661

,,/-aminobutyric acid and release of, 414, 416, 418

as an autocrine regulator, 407 in brain stem, 407 calcium and, 414, 420 comparisons of, 411 in cerebral cortex, 407 CNS distribution of, 407 discovery, 405 dopamine and, 316 effect on membrane permeability to calcium,

420 in feedback control of GH secretion, 317 GH inhibition of, 309 GH secretion and, 413 hGRF-NH 2 and, 394 in hippocampus, 407 hpGRF-40 and, 363 in the hypothalamus, 407, 409, 415-416 mechanism of action, 419-421 in neurophypophysis, 407 norepinephrine and, 316 oxytocin and, 407 as a paracrine regulator, 407 as prohormones, 413 purification, 325 receptors, 419-420 somatomedin C and, 317 in spinal cord, 407 structure, 405, 406 TSH and, 413, 417-419 as tumor marker, 375 vasopressin and, 407 verapamil and, release of, 414

Somatostatinoma syndrome, as marker of endocrine tumor, 382

Spinal cord, somatostatin in, 407 Strabismus, in LTD, 165 Substance P

GH and, 311, 312, 418 hypothalamic somatostatin and, 416, 418 TSH and, 418 as tumor marker, 375

Tennessee Self-Concept Scale, 94 Testicle, undescended, in LTD, 165 Thalassemia major, GH responses in, 60 Thyroid function, hGH therapy, 119

662

Thyroid hormone, 419 GH and, 179, 181 hypothalamic somatostatin and, 415

Thyroid-stimulating hormone (TSH), 2, 236 acetylcholine and, 418 'Y-aminobutyric acid and, 418 bombesin and, 418 cholecystokinin and, 418 deficiency, 68 dopamine and secretion of, 418 endorphins and, 418 glucagon and, 418 hpGRF-40 and, 362 hGRF 1-44-NH2 and, 394 melatonin and, 418 neurotensin and, 418 norepinephrine and release of, 418 TRH and, 418 secretin and, 418 serotonin and, 418 somatomedin C and, 418 somatostatins and, 413 substance P and, 418 VIP and, 418

Thyroidectomy, hypothalamic somatostatin and,415

Thyrotropin, see Thyroid-stimulating hormone (TSH)

Thyrotropin releasing hormone in acromegaly, 310 GH and, 37, 310, 312,418 receptors, in somatotrophs, 39 TSH and, 418

Thyroxine, 419 met-hGH and levels of, 271

TRH, see Thyrotropin releasing hormone Triiodothyronine, function, 419 Tryptophan, hGH levels and, 316

Index

TSH, see Thyroid-stimulating hormone (TSH) Tumor

GH-secreting, 29-36 classification of, 30

GRF-secreting, 348-354 pituitary, 29-36

Turner's syndrome, hGH therapy in, 109-113, 115-121

Uremia, 575-584; see also Renal failure growth impairment in, 575 IGF-I in, 606 somatomedin activity in, 578

Vasoactive intestinal polypeptide (VIP) GH and, 311, 312, 418 hypothalamic somatostatin and, 416, 417,

418 TSH and, 418 as tumor marker, 375

Vasopressin, 236 GH and, 310, 312 somatostatin and, 407

Verapamil GH release and, 334 somatostatin release and, 414

VIP, see Vasoactive intestinal polypeptide (VIP)

Western blotting, 261, see also Immunoblotting assay

Wound healing, hpGRF in, 370